RARB and colon adenocarcinoma: Fen can be considered a suitable drug in colon adenocarcinoma since this disease is characterized by the downregulation of the retinoic acid receptor, and Fen has been proved to increase RARβ expression in a wide range of cancer cells, including colon adenocarcinoma.